The nanoemulsion delivery system developer raised series A funding from Haohai Biological alongside an $8m payment for the Chinese rights to its products.
Biomedical product provider Shanghai Haohai Biological Technology agreed yesterday to help provide $32m in series A funding for US-based aesthetic dermatology technology developer Eirion Therapeutics.
Eirion is the creator of a device that uses a nanoemulsion delivery system to create temporary micropores in the skin to make topical neuromodulator treatments less painful and reduce bleeding.
Haohai will also make an $8m upfront payment for the Chinese rights to Eirion’s products, and the overall funding deal will be structured over an…
